KPTI - Karyopharm Therapeutics Inc Stock Price, Fair Value and News

1.02USD-0.08 (-7.27%)Market Closed

Market Summary

USD1.02-0.08

Market Closed

-7.27%

KPTI Stock Price

View Fullscreen

KPTI RSI Chart

KPTI Valuation

Market Cap

120.1M

Price/Earnings (Trailing)

-0.82

Price/Sales (Trailing)

0.85

EV/EBITDA

-0.73

Price/Free Cashflow

-1.02

KPTI Price/Sales (Trailing)

KPTI Profitability

EBT Margin

-103.94%

Return on Equity

86.61%

Return on Assets

-71.57%

Free Cashflow Yield

-98.06%

KPTI Fundamentals

KPTI Revenue

Revenue (TTM)

140.5M

Rev. Growth (Yr)

-14.4%

Rev. Growth (Qtr)

-1.84%

KPTI Earnings

Earnings (TTM)

-146.3M

Earnings Growth (Yr)

-9.48%

Earnings Growth (Qtr)

10.7%

Breaking Down KPTI Revenue

Last 7 days

-5.6%

Last 30 days

-24.4%

Last 90 days

-32.4%

Trailing 12 Months

-59.0%

How does KPTI drawdown profile look like?

KPTI Financial Health

Current Ratio

3.04

KPTI Investor Care

Shares Dilution (1Y)

3.25%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	140.5M	0	0	0
2023	148.1M	146.0M	145.9M	146.0M
2022	234.2M	251.3M	249.8M	157.1M
2021	113.2M	102.3M	118.7M	209.8M
2020	58.9M	82.9M	91.1M	108.1M
2019	33.0M	35.6M	38.3M	40.9M
2018	16.5M	31.4M	31.7M	30.3M
2017	222.0K	567.8K	1.3M	1.6M
2016	0	309.0K	207.0K	179.0K
2015	0	208.0K	262.0K	266.0K
2014	325.0K	213.0K	234.0K	229.0K
2013	833.0K	433.0K	399.0K	387.0K
2012	272.5K	393.0K	513.5K	634.0K
2011	0	0	0	152.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Karyopharm Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	paulson richard a.	sold	-4,040	1.13	-3,576	president and ceo
Apr 22, 2024	rangwala reshma	sold	-7,943	1.17	-6,789	evp & chief medical officer
Apr 04, 2024	paulson richard a.	sold	-4,596	1.29	-3,563	president and ceo
Mar 05, 2024	paulson richard a.	sold	-4,644	1.3	-3,573	president and ceo
Mar 01, 2024	paulson richard a.	sold	-23,248	1.2	-19,374	president and ceo
Mar 01, 2024	rangwala reshma	sold	-7,162	1.2	-5,969	evp & chief medical officer
Mar 01, 2024	poulton stuart	sold	-7,386	1.2	-6,155	evp, chief development officer
Mar 01, 2024	mason michael	sold	-7,394	1.2	-6,162	evp, cfo & treasurer
Mar 01, 2024	cheng sohanya roshan	sold	-6,130	1.2	-5,109	evp & chief commercial officer
Mar 01, 2024	mano michael	sold	-4,291	1.2	-3,576	svp, general counsel&secretary

Which funds bought or sold KPTI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SEI INVESTMENTS CO	new	-	60,398	60,398	-%
May 07, 2024	Headlands Technologies LLC	new	-	1,875	1,875	-%
May 07, 2024	Redwood Wealth Management Group, LLC	sold off	-100	-25,716	-	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	added	9.17	15,000	32,000	-%
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	added	1.09	150,445	347,185	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-2.54	47,678	115,664	-%
May 06, 2024	Candriam S.C.A.	sold off	-100	-459,071	-	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-433	-	-%
May 06, 2024	SG Americas Securities, LLC	sold off	-100	-64,000	-	-%
May 03, 2024	C WorldWide Group Holding A/S	unchanged	-	967,000	2,265,000	0.03%

Are Funds Buying or Selling KPTI?

Are funds buying KPTI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KPTI

No. of Funds

Unveiling Karyopharm Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	avidity partners management lp	9.5%	11,188,743	SC 13G/A
Feb 14, 2024	palo alto investors lp	4.45%	5,102,193	SC 13G/A
Feb 13, 2024	vanguard group inc	7.60%	8,710,158	SC 13G
Feb 12, 2024	rubric capital management lp	0%	0	SC 13G/A
Jan 25, 2024	blackrock inc.	8.8%	10,071,677	SC 13G/A
Jan 22, 2024	state street corp	1.79%	2,053,773	SC 13G/A
Jul 10, 2023	state street corp	1.94%	2,212,367	SC 13G/A
Feb 14, 2023	avidity partners management lp	9.9%	11,381,073	SC 13G/A
Feb 14, 2023	palo alto investors lp	5.00%	5,655,676	SC 13G/A
Feb 14, 2023	chione ltd	3.9%	4,400,000	SC 13G/A

Recent SEC filings of Karyopharm Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 08, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 19, 2024	DEFA14A	DEFA14A
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	ARS	ARS
Apr 08, 2024	PRE 14A	PRE 14A
Apr 08, 2024	SC TO-C	SC TO-C

Peers (Alternatives to Karyopharm Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Karyopharm Therapeutics Inc News

Latest updates

Karyopharm Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-1.8%	33,126,000	33,747,000	36,009,000	37,579,000	38,698,000	33,580,000	36,145,000	39,679,000	47,670,000	126,269,000	37,689,000	22,601,000	23,260,000	35,100,000	21,333,000	33,514,000	18,138,000	18,096,000	13,149,000	9,493,000	4,849,500
Operating Expenses	-6.5%	66,885,000	71,555,000	67,269,000	67,152,000	69,597,000	67,449,000	66,984,000	82,587,000	82,256,000	79,307,000	81,501,000	71,649,000	75,633,000	72,166,000	68,442,000	73,833,000	65,494,000	61,362,000	52,550,000	51,179,000	65,077,000
S&GA Expenses	-3.7%	29,549,000	30,688,000	30,805,000	34,481,000	35,907,000	34,649,000	34,645,000	37,339,000	38,768,000	34,562,000	35,104,000	36,530,000	37,650,000	33,929,000	30,967,000	30,843,000	30,678,000	28,389,000	25,267,000	24,662,000	27,103,000
R&D Expenses	-10.0%	35,425,000	39,381,000	35,553,000	31,477,000	32,339,000	30,932,000	31,359,000	44,309,000	42,062,000	44,003,000	45,808,000	33,981,000	37,050,000	37,185,000	37,037,000	42,594,000	33,997,000	31,579,000	26,270,000	26,517,000	37,974,000
EBITDA Margin	-6.7%	-0.87	-0.81	-0.79	-0.80	-0.90	-0.89	-0.24	-0.29	-0.34	-0.46	-1.51	-1.79	-	-	-	-	-	-	-	-	-
Interest Expenses	-5.2%	5,884,000	6,208,000	6,073,000	5,784,000	5,758,000	5,885,000	6,114,000	6,313,000	6,684,000	7,940,000	8,010,000	5,001,000	5,095,000	7,072,000	6,801,000	6,758,000	6,509,000	6,467,000	3,093,000	3,089,000	2,998,000
Income Taxes	-33.6%	71,000	107,000	12,000	127,000	54,000	104,000	45,000	121,000	130,000	-89,000	106,000	134,000	149,000	53,000	44,000	137,000	66,000	2,000	20,000	8,000	10,000
Earnings Before Taxes	10.6%	-37,291,000	-41,707,000	-34,494,000	-32,503,000	-34,072,000	-38,433,000	-36,279,000	-48,941,000	-41,269,000	38,599,000	-51,706,000	-53,448,000	-57,265,000	-43,359,000	-53,451,000	-46,289,000	-52,865,000	-48,645,000	-41,347,000	-43,407,000	-66,151,000
EBT Margin	-6.3%	-1.04	-0.98	-0.96	-0.97	-1.06	-1.05	-0.35	-0.41	-0.46	-0.59	-1.73	-2.03	-	-	-	-	-	-	-	-	-
Net Income	10.7%	-37,362,000	-41,837,000	-34,506,000	-32,630,000	-34,126,000	-38,506,000	-36,324,000	-49,062,000	-41,399,000	38,720,000	-51,812,000	-53,582,000	-57,414,000	-43,421,000	-53,495,000	-46,426,000	-52,931,000	-48,647,000	-41,367,000	-43,415,000	-66,161,000
Net Income Margin	-6.3%	-1.04	-0.98	-0.96	-0.97	-1.07	-1.05	-0.35	-0.41	-0.46	-0.59	-1.74	-2.03	-	-	-	-	-	-	-	-	-
Free Cashflow	-136.3%	-43,920,000	-18,585,000	-29,530,000	-25,698,000	-18,910,000	-26,843,000	-28,409,000	-35,144,000	-59,276,000	25,268,000	-23,960,000	-55,748,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-15.0%	204	240	270	298	326	358	231	256	294	305	254	287	275	313	338	380	416	295	298	238	287
Current Assets	-15.2%	198	234	263	291	319	350	223	242	277	276	242	274	256	277	285	318	371	279	281	223	271
Cash Equivalents	-39.9%	31.00	52.00	44.00	81.00	84.00	135	71.00	82.00	153	190	137	141	88.00	89.00	82.00	103	202	131	168	76.00	84.00
Inventory	-9.0%	3.00	3.00	3.00	4.00	4.00	4.00	4.00	3.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00	1.00	0.00	0.00	-	-
Net PPE	18.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	4.00
Liabilities	-0.9%	373	377	370	369	371	375	372	373	377	385	380	370	315	263	254	250	250	245	238	156	166
Current Liabilities	-6.0%	65.00	69.00	62.00	59.00	62.00	66.00	62.00	63.00	66.00	74.00	69.00	58.00	62.00	60.00	53.00	51.00	50.00	46.00	39.00	32.00	44.00
Shareholder's Equity	-24.0%	-168	-136	-	-	-45.17	-16.66	-	-	-	-	-	-	-	51.00	84.00	130	166	50.00	60.00	82.00	121
Retained Earnings	-1.6%	-1,524	-1,500	-1,445	-1,410	-1,378	-1,343	-1,305	-1,269	-1,220	-1,178	-1,217	-1,165	-1,111	-15.00	-1,026	-972	-926	-873	-824	-783	-739
Additional Paid-In Capital	0.4%	1,356	1,351	1,346	1,340	1,333	1,328	1,166	1,153	1,137	1,099	1,091	1,082	1,072	1,120	1,109	1,102	1,093	923	885	866	861
Shares Outstanding	1.3%	116	115	115	114	114	113	79.00	79.00	78.00	75.00	75.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	201	-	-	-	351	-	-	-	739	-	-	-	1,320	-	-	-	344	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-135.3%	-43,725	-18,585	-29,530	-25,698	-18,910	-26,843	-28,370	-35,144	-59,197	25,475	-23,955	-55,748	-52,888	-30,634	-44,312	-40,277	-45,011	-39,489	-36,506	-48,204	-66,623
Share Based Compensation	-4.1%	4,970	5,182	5,078	6,060	5,389	6,173	6,797	15,093	7,336	6,869	7,420	8,135	7,359	6,314	6,513	6,428	5,152	3,549	3,719	4,116	3,907
Cashflow From Investing	-18.3%	21,940	26,843	-7,685	21,170	-32,388	-65,298	11,673	-36,596	-14,035	30,770	21,426	46,458	43,186	31,397	21,431	-60,034	-46,479	-33,519	40,175	39,803	31,991
Cashflow From Financing	-100.0%	-	264	-	860	-	155,843	5,799	1,313	30,783	896	16.00	62,060	10,676	3,968	1,240	2,046	164,829	34,936	88,822	395	152

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KPTI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenue from contract with customer, license and other revenue	$ 146,033	$ 157,074	$ 209,819
Operating expenses:
Research and development	138,750	148,662	160,842
Selling, general and administrative	131,881	145,401	143,846
Total operating expenses	275,573	299,276	308,090
Loss from operations	(129,540)	(142,202)	(98,271)
Other income (expense):
Interest income	10,943	2,359	582
Interest expense	(23,823)	(24,996)	(26,046)
Other expense, net	(356)	(83)	(85)
Total other expense, net	(13,236)	(22,720)	(25,549)
Loss before income taxes	(142,776)	(164,922)	(123,820)
Income tax provision	(323)	(369)	(268)
Net loss	$ (143,099)	$ (165,291)	$ (124,088)
Net loss per share - basic	$ (1.25)	$ (2.02)	$ (1.65)
Net loss per share - diluted	$ (1.25)	$ (2.02)	$ (1.65)
Weighted-average number of common shares outstanding used to compute net loss per share - basic	114,221,000	81,871,000	75,218,000
Weighted-average number of common shares outstanding used to compute net loss per share - diluted	114,221,000	81,871,000	75,218,000
Product [Member]
Revenues:
Revenue from contract with customer, license and other revenue	$ 112,011	$ 120,445	$ 98,436
Operating expenses:
Cost of sales	4,942	5,213	3,402
License and Other [Member]
Revenues:
Revenue from contract with customer, license and other revenue	$ 34,022	$ 36,629	$ 111,383

KPTI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 52,231	$ 135,188
Investments	139,212	142,779
Accounts receivable,net	26,962	47,086
Inventory	3,043	4,224
Prepaid expenses and other current assets	11,813	19,821
Restricted cash	660	1,064
Total current assets	233,921	350,162
Property and equipment, net	606	1,139
Operating lease right-of-use assets	4,276	6,238
Restricted cash	301	633
Other assets	1,334	0
Total assets	240,438	358,172
Current liabilities:
Accounts payable	3,123	2,773
Accrued expenses	61,394	58,415
Operating lease liabilities	3,308	2,872
Other current liabilities	1,654	1,848
Total current liabilities	69,479	65,908
Convertible senior notes	170,919	170,105
Deferred royalty obligation	132,479	132,718
Operating lease liabilities, net of current portion	2,789	6,097
Other liabilities	978	0
Total liabilities	376,644	374,828
Stockholders' deficit
Preferred stock, $0.0001 par value; 5,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value; 4000,000 shares authorized; 114,915 shares issued and outstanding at December 31, 2023; 200,000 shares authorized; 113,213 shares issued and outstanding at December 31, 2022	12	12
Additional paid-in capital	1,350,981	1,327,909
Accumulated other comprehensive loss	(161)	(638)
Accumulated deficit	(1,487,038)	(1,343,939)
Total stockholders' deficit	(136,206)	(16,656)
Total liabilities and stockholders' deficit	$ 240,438	$ 358,172

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

CEO	Mr. Richard A. Paulson M.B.A.
WEBSITE	karyopharm.com
INDUSTRY	Biotechnology
EMPLOYEES	385

Karyopharm Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Karyopharm Therapeutics Inc? What does KPTI stand for in stocks?

KPTI is the stock ticker symbol of Karyopharm Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Karyopharm Therapeutics Inc (KPTI)?

As of Wed May 08 2024, market cap of Karyopharm Therapeutics Inc is 117.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KPTI stock?

You can check KPTI's fair value in chart for subscribers.

What is the fair value of KPTI stock?

You can check KPTI's fair value in chart for subscribers. The fair value of Karyopharm Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Karyopharm Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KPTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Karyopharm Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KPTI is over valued or under valued. Whether Karyopharm Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karyopharm Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KPTI.

What is Karyopharm Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, KPTI's PE ratio (Price to Earnings) is -0.82 and Price to Sales (PS) ratio is 0.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPTI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Karyopharm Therapeutics Inc's stock?

In the past 10 years, Karyopharm Therapeutics Inc has provided -0.278 (multiply by 100 for percentage) rate of return.